The effect of tubeimoside-1 on the proliferation, metastasis and apoptosis of oral squamous cell carcinoma in vitro

Abstract

BackgroundTubeimoside-1 (TBMS1), a triterpenoid saponin extracted from traditional Chinese medicine tubeimoside, exerts a cytotoxic effect on several human cancer cell lines. However, no study has focused on whether TBMS1 works on oral squamous cell carcinoma (OSCC).Materials and methodsWe treated OSCC cells with TBMS1 to detect the effect and relevant molecular basis of TBMS1 for the first time. We chose two oral cancer cell lines, CAL27 and SCC15, for this study. First, the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenylte-trazolium bromide assay and cell proliferation 5′-bromo-2′-deoxyuridine assay were carried out to detect cell growth. Second, colony formation assay was performed to assess clonogenesis capacity. Next apoptosis was analyzed by flow cytometry. Subsequently, wound healing and transwell assays were applied to explore cell migration. Finally, Western blot was further performed to examine corresponding proteins’ expression change.ResultsOur data showed that TBMS1 significantly suppressed proliferation of OSCC cells in a dose- and time-dependent manner and it inhibited migration of OSCC cells as well. After treatment with TBMS1, OSCC cells underwent cell apoptosis. Furthermore, Western blot demonstrated that TBMS1 downregulated apoptosis-associated proteins such as PARP, p-ERK1/2, Bcl-2, caspase-3, caspase-7 and caspase-8 and upregulated cleaved PARP, cleaved caspase-3 and cleaved caspase-9. It could also reduce expression of c-Myc and MMP-7. Meanwhile, TBMS1 did not change the total ERK1/2 expression.ConclusionThese results revealed that TBMS1 might be a potential chemotherapeutic drug for the management of OSCC.

Alkannin restrains oral squamous carcinoma cell growth, migration and invasion by regulating microRNA-9/RECK axis

“…Evidence from Yang et al [24] discovered that Icaritin could repress the progression of OSCC through hindering STAT3 signalling. In addition, Tubeimoside-1 (TBMS1) has been certified to refrain OSCC cell proliferation, migration and to accelerate apoptosis in vitro [25]. These findings seem to hint that TCMs are an effective agent for OSCC treatment.…”

Tubeimoside-1 Protects Against Renal Ischemia Reperfusion Injury In Vivo and In Vitro

“…[7][8][9] Tubeimoside-1 (TBMS1) is the main active ingredient of Rhizoma bolbostemmae, and studies have demonstrated that it suppresses proliferation and induces apoptosis of cells in cancers such as glioma, 10 glioblastoma, 11 non-small-cell lung cancer, 12 and oral squamous cell carcinoma. 13 TBMS1 is conventionally used to treat snake venoms and inflammation, and was included in Supplements to Compendium of Materia Medica published in 1765. 14 Furthermore, in acute lung-injured mice, TBMS1 could alleviate inflammation in lipopolysaccharide-induced RAW 264.7 cells.…”

Tubeimoside-1 Inhibits Glioblastoma Growth, Migration, and Invasion via Inducing Ubiquitylation of MET

“…The highest-acquired active monomer TBMS1 which extracted from the tubers of Rhizoma Bolbostemmatis has proven its potential ability in the treatment of gastric cancer, liver cancer, cervical cancer, lung cancer, ovarian cancer, glioblastoma, esophageal cancer, etc [5,6,7,8,9,10]. At present, the anti-tumor mechanism of TBMS1 has been found to induce anti-tumor effects by inducing apoptosis [11,12], autophagy [13], cell cycle arrest [14,15], inhibition of cancer cell growth, metastasis [16], differentiation [17], angiogenesis [18] and inflammation [19]. Although the relevant critical pathways and molecular targets of TBMS1 have been confirmed, we need to further improve and explore the relevant mechanisms for the possible therapeutic application to the treatment of cancer.…”